Transforming treatments for neurotrauma and neurovascular disorders

BioAxone is developing a suite of game-changing treatments for spinal cord injury, neurovascular diseases, and eye disorders by targeting Rho/Rho kinase signaling pathways involved in a variety of pathological processes.

Like Comment
Page of
Go to the profile of BioAxone BioSciences, Inc.

BioAxone BioSciences, Inc.

BioAxone is an emerging clinical stage company that creates innovative medicines for neurological disorders and neurotrauma. The company’s Phase 2 drug VX-210, was licensed to Vertex Pharmaceuticals in 2014 and is now in Phase 2b/3 clinical study for treatment of acute cervical spinal cord injury. The company has a research partnership with RXi Pharmaceuticals for a second pipeline drug in development to treat spinal cord injury. The company’s lead drug, BA-1049 is IND-ready and is development for treatment of cerebral cavernous malformation (CCM), a neurovascular disorder caused by loss of CCM gene function. CCM is a cerebrovascular orphan disease, and the loss of blood brain barrier function is a mechanism in common with other cerebrovascular diseases, such as stroke. The company goal is to form partnerships with world-class biopharmaceutical companies to accelerate clinical development and commercialization of drugs for the serious unmet needs in neurotrauma and neurovascular disease.

No comments yet.